Presenting on the above topic is Prof Ceri Davies, Vice President, Head of GSK Singapore R&D Site, Head of Neural Pathways DPU, GSK, Singapore. He will be speaking at Drug Discovery World Asia 2012, part of a series of conferences at 5th Annual BioPharma Asia Convention 2012.
Professor Ceri Davies graduated from the University of Bristol with a first class honours degree and PhD in pharmacology and ran an independent academic laboratory at the University of Edinburgh before leaving academia in 1998 to join the pharmaceutical industry at Organon Laboratories Scotland and subsequently SmithKline Beecham and GlaxoSmithKline at Harlow and Verona. During his pharmaceutical career he has led a number of research departments and has also been the principal scientist in charge of several research programmes at preclinical and clinical phases for both psychiatric and neurodegenerative disorders.
He has published over 80 full papers in peer reviewed scientific journals and has been awarded AJ Clark Scholarship and Novartis Prizes by the British Pharmacological Society in recognition of his pharmacological expertise. He is a visiting Honorary Professor in Neuroscience and Biomedical Systems at The University of Glasgow, a Fellow of the British Pharmacological Society and currently heads up the Singapore R&D Site and the Neural Pathways DPU which forms part of the R&D China Neurodegeneration Organization at GlaxoSmithKline.
Prof Davies will be speaking about the following topics:
Formulating innovative and effective therapeutic treatments for neurodegenerative diseases
1. Ameliorating neurodegenerative treatment efficacy without compromising protein aggregation
2. Optimizing functional magnetic resonance imaging (fMRI) to accelerate drug development for central nervous system disorders
3. Exploring novel therapeutic strategies for neurodegenerative diseases using JM6 treatment